Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.68 |
| ▸ | ACHE | P22303 | 4/20 | 0.57 |
| ▸ | PDE2A | O00408 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | NT5E | P21589 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | PGK1 | P00558 | 3/20 | 0.42 |
| ▸ | PGK2 | P07205 | 3/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9098922 | 0.80 | PDE2A (0.65) | BCHEPDE2AHTR1AADORA3NT5E | |
| SCHEMBL11420439 | 0.77 | PDE2A (0.61) | BCHEPDE2AHTR1AADORA2ATP53 | |
| SCHEMBL11516707 | 0.77 | ALDH1A1 (0.65) | ACHEADORA3ADORA2AADORA1TP53 | |
| SCHEMBL9097705 | 0.76 | PDE2A (0.70) | BCHEACHEPDE2AHTR1AADORA3 | |
| SCHEMBL8764444 | 0.76 | PDE2A (0.70) | BCHEPDE2AHTR1AADORA3ADORA2A | |
| SCHEMBL750344 | 0.76 | PDE2A (0.72) | BCHEPDE2AHTR1AADORA3ADORA2A | |
| SCHEMBL8610091 | 0.75 | TYMP (0.52) | ACHEADORA3ADORA2AADORA1NT5E | |
| SCHEMBL8611454 | 0.75 | TYMP (0.52) | ACHEADORA1NT5E | |
| SCHEMBL2221683 | 0.75 | ADORA2A (0.59) | ADORA3ADORA2AADORA1TP53 | |
| SCHEMBL2221692 | 0.75 | ADORA2A (0.59) | ADORA3ADORA2AADORA1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430032-B1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | ALCAFLEU MAN GMBH & CO KG (DE) | 2016-02-17 | — | — | EP | disclosed |
| US-20120220762-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | ALCAFLEU MANAGEMENT GMBH & CO. KG (DE) | 2012-08-30 | — | — | US | disclosed |
| EP-2430032-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | Alcafleu Management GmbH & Co. KG (DE) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130778-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | ALCAFLEU MANAGEMENT GMBH & CO. KG (DE) | 2010-11-18 | — | — | WO | disclosed |
| US-5180824-A | 6-AZIDO-2-FLUOROPURINE, USEFUL IN THE SYNTHESIS OF NUCLEOSIDES | BERLEX BIOSCIENCES INC. (US) | 1993-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220762-A1 | METHOD FOR THE MANUFACTURE OF 2-FLUORO-ARA-ADENINE | CD38, FLAD1, GART | BCHE 4309/4885ACHE 3676/4885PDE2A 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.